Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Castellano

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
ESMO Open|May 13, 2021
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapyA Bamias, A S Merseburger, Y Loriot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2011
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activityJ Bellmunt, J L González-Larriba, C Prior, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2023
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinomaJ E Rosenberg, T Powles, G P Sonpavde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancerJ Bellmunt, B J Eigl, E Senkus, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 29, 2020
Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer GroupJ Aparicio, X García Del Muro, P Maroto, et al.
Cancer Treatment Reviews|January 16, 2021
Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near futureM Rey-Cárdenas, F Guerrero-Ramos, A Gómez de Liaño Lista, et al.
ESMO Open|August 29, 2022
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket studyV Boni, B Pistilli, I Braña, et al.
Physical Review Letters|March 22, 2021
Emulating Quantum Teleportation of a Majorana Zero Mode QubitHe-Liang Huang, Marek Narożniak, Futian Liang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2025
Final overall survival and safety analyses of the phase III PSMAfore trial of [<sup>177</sup>Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancerK Fizazi, K N Chi, N D Shore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2015
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)E Grande, J Capdevila, D Castellano, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
ESMO Open|May 13, 2021
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapyA Bamias, A S Merseburger, Y Loriot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2011
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activityJ Bellmunt, J L González-Larriba, C Prior, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2023
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinomaJ E Rosenberg, T Powles, G P Sonpavde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancerJ Bellmunt, B J Eigl, E Senkus, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 29, 2020
Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer GroupJ Aparicio, X García Del Muro, P Maroto, et al.
Cancer Treatment Reviews|January 16, 2021
Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near futureM Rey-Cárdenas, F Guerrero-Ramos, A Gómez de Liaño Lista, et al.
ESMO Open|August 29, 2022
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket studyV Boni, B Pistilli, I Braña, et al.
Physical Review Letters|March 22, 2021
Emulating Quantum Teleportation of a Majorana Zero Mode QubitHe-Liang Huang, Marek Narożniak, Futian Liang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2025
Final overall survival and safety analyses of the phase III PSMAfore trial of [<sup>177</sup>Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancerK Fizazi, K N Chi, N D Shore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2015
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)E Grande, J Capdevila, D Castellano, et al.
Pageof 8